Diabetes Devices Market Size & Growth Forecast 2027–2036, By Segments (End-use, Distribution Channel, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Diabetes Devices Market size was assessed at USD 50.6 billion in 2026 and is poised to grow at a 9.98% CAGR between 2027 and 2036, attaining USD 131 billion by 2036. The industry revenue for 2027 is calculated at USD 54.85 billion.

• Base Year Value (2026): USD 50.6 billion
• CAGR (2027-2036): 9.98%
• Forecast Year Value (2036): USD 131 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Diabetes Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to widespread CGM and insulin device adoption, strong reimbursement systems, mature clinical integration, and presence of major manufacturers driving steady replacement demand.
  • Asia Pacific growth is driven by 8.59% CAGR, rising diabetes burden, expanding diagnosis access, urbanization, and increased shift toward continuous glucose monitoring and home-based care.

• Segment Momentum:

  • Hospitals accounted for 43.25% of the market in 2026 because they combine diabetes diagnosis, treatment initiation, monitoring, and complication management with integrated clinical support, making them the primary setting for complex patient care.
  • Retail pharmacies are expanding the fastest because they provide convenient, repeat access to diabetes devices and supplies, supporting routine purchasing behavior and reducing the need for frequent hospital visits.

• Market Expansion Drivers:

  • Rising global diabetes and obesity prevalence driving demand for monitoring and insulin devices.
  • AI-enabled continuous glucose monitoring and connected insulin delivery systems enhancing personalized diabetes management.
  • Expanding adoption of affordable home-based diabetes monitoring solutions across emerging markets.

• Leading Market Participants:

  Prominent companies in the diabetes devices market include Medtronic plc (Ireland), Abbott Laboratories (United States), Dexcom Inc. (United States), Insulet Corporation (United States), Becton Dickinson and Company (United States), Novo Nordisk A/S (Denmark), Sanofi (France), Roche Diabetes Care (Switzerland), B. Braun Melsungen AG (Germany), Arkray Inc. (Japan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 50.6 billion
  • 2027 Estimated Market Size: USD 54.85 billion.
  • Projected Market Size: USD 131 billion by 2036
  • Growth Forecasts: 9.98% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Hospitals (End-use) | Hospital Pharmacies (Distribution Channel) | BGM Devices (Type)
  • Emerging Opportunity Segment: Diagnostic Centers (End-use) | Retail Pharmacies (Distribution Channel) | Insulin Delivery Devices (Type)

Market Growth Drivers and Industry Trends

Rising global diabetes and obesity prevalence driving demand for monitoring and insulin devices

The growing prevalence of diabetes and obesity is creating a larger population requiring continuous disease management, which will drive the diabetes devices market growth. Patients and healthcare providers increasingly rely on blood glucose monitors, continuous glucose monitoring systems, insulin pumps, and related delivery devices to track glucose levels and manage insulin requirements. The increasing emphasis on maintaining glucose control and reducing complications is also encouraging greater use of monitoring and insulin technologies across clinical and home-care settings.

AI-enabled continuous glucose monitoring and connected insulin delivery systems enhancing personalized diabetes management

Integration of artificial intelligence and connectivity into diabetes management technologies will propel the diabetes devices market growth by enabling more responsive and individualized disease management. AI-enabled systems can analyze glucose patterns, identify changes in patient data, and support more informed treatment decisions, while connected insulin delivery devices can coordinate monitoring information with insulin administration. Integration with digital health platforms and mobile applications also allows patients and clinicians to access real-time information, supporting more personalized management of changing glucose levels.

Expanding adoption of affordable home-based diabetes monitoring solutions across emerging markets

Greater availability of cost-effective monitoring technologies is expanding access to diabetes management outside traditional healthcare facilities, thereby boosting the diabetes devices market demand across emerging markets. Home-based glucose monitoring enables patients to track their condition more frequently while reducing the need for routine facility visits, which is particularly relevant where healthcare infrastructure and specialist access remain uneven. Increasing awareness of diabetes management, wider distribution networks, and the availability of simpler portable devices are supporting adoption among patients seeking convenient monitoring options.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global diabetes and obesity prevalence driving demand for monitoring and insulin devices	2.10%	High	North America, Europe, Asia Pacific	High	Near Term
AI-enabled continuous glucose monitoring and connected insulin delivery systems enhancing personalized diabetes management	1.90%	High	North America, Europe	High	Mid Term
Expanding adoption of affordable home-based diabetes monitoring solutions across emerging markets	1.50%	Moderate	Asia Pacific, Latin America, Middle East & Africa	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the diabetes devices market in 2026, supported by the region’s well-established healthcare infrastructure, strong adoption of advanced medical technologies, and widespread availability of diabetes management solutions. High awareness of continuous disease monitoring, increasing emphasis on preventive care, and the integration of connected and digital health technologies are strengthening demand for diabetes devices. Favorable reimbursement environments and the presence of specialized healthcare facilities further support access to sophisticated monitoring and insulin delivery systems, while ongoing efforts to improve patient convenience and treatment outcomes continue to reinforce the region’s market leadership.

Asia Pacific is expected to be the fastest-growing region, driven by the expanding burden of diabetes, rising healthcare expenditure, and improving access to diagnostic and disease management technologies. Growing urbanization and changing lifestyles are increasing the need for regular glucose monitoring and effective long-term diabetes care across the region. At the same time, expanding healthcare infrastructure, greater awareness of early diagnosis, and increasing adoption of digital health solutions are creating favorable conditions for wider use of advanced diabetes devices. Government initiatives aimed at strengthening chronic disease management and the growing availability of healthcare services in emerging economies are also supporting the region’s growth trajectory.

Key Country Insights

United States

Connected Diabetes Management

The U.S. diabetes devices market continues integrating continuous glucose monitoring, insulin delivery technologies, and digital health platforms. Healthcare providers and patients increasingly adopt connected solutions that improve treatment management and long-term disease monitoring.

Japan

Patient-Centric Device Innovation

Japan advances diabetes device adoption through compact monitoring systems, user-friendly insulin delivery solutions, and digital disease management tools. Manufacturers prioritize reliability and ease of use to support consistent long-term diabetes care.

South Korea

Digital Care Integration

South Korea expands diabetes device utilization by integrating connected monitoring technologies with digital healthcare services. Growing adoption of smart medical devices supports more efficient disease management and improved patient engagement across care settings.

Germany

Precision Monitoring Adoption

Germany focuses on diabetes devices that enhance glucose monitoring accuracy and support personalized treatment decisions. Healthcare systems encourage the use of advanced monitoring technologies that improve patient management and clinical efficiency.

France

Clinical Monitoring Enhancement

France strengthens the diabetes devices market through wider use of advanced glucose monitoring technologies and integrated patient management solutions. Healthcare providers increasingly emphasize early intervention and data-driven treatment optimization for chronic disease management.

Italy

Accessible Disease Monitoring

Italy promotes diabetes devices that improve routine glucose monitoring and support effective long-term disease management. Demand continues shifting toward reliable, patient-friendly technologies that simplify treatment adherence across both clinical and home care environments.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Centers (Fastest-Growing Segment)

Hospitals represented the largest end-use segment in the diabetes devices market, accounting for 43.25% in 2026. Hospitals manage substantial volumes of patients requiring diabetes screening, monitoring, diagnosis, and ongoing disease management, creating sustained demand for specialized devices. The availability of clinical infrastructure and healthcare professionals enables the use of multiple diagnostic and monitoring technologies within hospital settings. Increasing emphasis on early detection and effective diabetes management continues to support hospital-based utilization.

Diagnostic centers are the fastest-growing end-use segment as testing becomes increasingly important for identifying diabetes and monitoring metabolic health outside conventional hospital environments. Diagnostic centers provide dedicated testing capabilities and can support convenient access to laboratory and diagnostic services. Growing awareness of diabetes screening and increasing demand for timely diagnostic evaluation are expanding the role of these facilities in diabetes care.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

Hospital pharmacies accounted for the largest share of the diabetes devices market, representing 56.84% in 2026. These pharmacies are closely integrated with clinical care and can provide patients with access to prescribed diabetes devices and related supplies during or after hospital treatment. Their proximity to physicians and other healthcare professionals supports coordinated product selection and patient education. The continued importance of institutional diabetes management contributes to the strong position of hospital pharmacies.

Retail pharmacies are the fastest-growing distribution channel as diabetes management increasingly extends into community and home settings. Patients require convenient access to monitoring devices, testing supplies, and other diabetes-related products outside hospitals, making retail pharmacies an important point of purchase. Their broad geographic accessibility and ability to serve recurring consumer needs are supporting greater utilization. The growing emphasis on self-management of diabetes is further strengthening this channel.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Hospitals, Diagnostic Centers, Homecare	Hospitals	Diagnostic Centers
Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies, Others	Hospital Pharmacies	Retail Pharmacies
Type	BGM Devices, Insulin Delivery Devices	BGM Devices	Insulin Delivery Devices

Competitive Landscape and Market Positioning

Prominent players in the diabetes devices market:

1. Medtronic plc (Ireland)

2. Abbott Laboratories (United States)

3. Dexcom Inc. (United States)

4. Insulet Corporation (United States)

5. Becton Dickinson and Company (United States)

6. Novo Nordisk A/S (Denmark)

7. Sanofi (France)

8. Roche Diabetes Care (Switzerland)

9. B. Braun Melsungen AG (Germany)

10. Arkray Inc. (Japan)

The diabetes devices market is advancing through continuous innovation in continuous glucose monitoring systems, smart insulin delivery devices, and connected diabetes management platforms. Integration of mobile health applications and real-time monitoring technologies is improving patient convenience and supporting wider adoption of personalized diabetes care solutions.

Industry Development/News

Company Name	Date	Key Development
Insulet	May-26	Insulet initiated a clinical study to evaluate its fully automated closed-loop insulin delivery system specifically for patients with Type 2 diabetes. This development represents a strategic expansion of the company’s automated insulin delivery (AID) portfolio, aiming to address the significant and growing clinical need for advanced technology solutions among the non-insulin-dependent and insulin-requiring Type 2 diabetic population.
Medtronic; Abbott	Sep-25	The U.S. FDA cleared the integration of Medtronic’s MiniMed 780G insulin pump with Abbott’s integrated continuous glucose monitor (iCGM) sensor, simultaneously approving the system for use in adults with insulin-requiring Type 2 diabetes. This partnership between two major industry players significantly broadens the market for automated insulin delivery systems and enhances interoperability for patients managing Type 2 diabetes.
Medtronic	Apr-26	Medtronic received Health Canada approval for new software updates for its MiniMed 780G system and Simplera Sync sensor, specifically tailored for Type 2 diabetes management. This regulatory milestone strengthens the company’s position in the Canadian market, facilitating the deployment of advanced, connected automated insulin delivery solutions for a broader range of diabetic patients.
Embecta	Mar-26	Embecta entered a definitive agreement to acquire Owen Mumford for approximately £100 million. This strategic move is intended to diversify Embecta’s product offering beyond traditional insulin delivery devices, broadening its medical device portfolio and enhancing its competitive standing in the wider diabetes management and chronic care technology sectors.
Senseonics Holdings; Ascensia	Sep-24	Senseonics and Ascensia received U.S. FDA clearance for the Eversense 365 system, the industry’s first implantable continuous glucose monitor (CGM) offering a one-year sensor life. This breakthrough technology represents a significant shift in long-term glucose monitoring, reducing the burden of frequent sensor changes and providing a distinct competitive alternative to traditional short-term patch CGM systems.
Luna Diabetes	Aug-25	Luna Diabetes secured $23.6 million in Series A funding to accelerate the commercialization of its automated insulin patch pump technology. This capital infusion supports the development of compact, wearable delivery solutions, reinforcing the company's position as an emerging innovator in the advanced, user-friendly insulin delivery device segment.
Sequel Med Tech; Senseonics	Apr-25	Sequel Med Tech partnered with Senseonics to integrate the Eversense 365-day CGM system with its forthcoming twiist automated insulin pump. By creating a highly connected, long-wear management system, this collaboration targets the Type 1 diabetes segment with a solution that prioritizes convenience and data integration, aiming to improve long-term patient adherence and glycemic outcomes.
Insulet	Jun-24	Insulet executed the full commercial launch of its Omnipod 5 automated insulin delivery system in the U.K. and the Netherlands, featuring expanded integration with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus sensors. This cross-platform compatibility increases patient flexibility and strengthens the company’s market presence by enabling choice in CGM hardware for integrated diabetes care.
Abbott; Medtronic	Aug-24	Abbott and Medtronic established a strategic partnership to develop a glucose sensor specifically engineered for seamless compatibility with Medtronic’s suite of insulin delivery technologies. This agreement signifies a commitment to enhanced system integration, aiming to improve the reliability and functional synergy of CGM and pump platforms for patients utilizing interconnected diabetes management solutions.
Modular Medical	Aug-25	Modular Medical introduced its next-generation Pivot insulin patch pump and initiated preparations for an FDA submission. The device is engineered to simplify the insulin delivery process, targeting market expansion by providing a lower-complexity, user-centric alternative for patients seeking a more accessible transition to advanced insulin pump therapy.